By Paul Perreault
March 7, 2017
One of the things I like to remind our people to do is remember where we came from. In reflecting on my recent interview with Medical Marketing & Media (MM&M) magazine, in which I talked about CSL Limited’s unique beginning as a government agency, it strikes me that we really are unlike other biotechs.
Founded by the Australian government in 1916, CSL was born to serve people. It wasn’t until 1994 that we were privatized. CSL was established to ensure a continuous supply of medicines to Australians would not be disrupted by World War I. As I mentioned in my interview, we started with a mindset that reflected our government heritage – we’re always scrapping.
Paradigm shift from doing to and for patients, to a more engaging environment of doing with patients
By Anthony Farina
Nearly every healthcare organization talks about putting patients first, but what does patient centricity really mean? CSL’s CEO and Managing Director Paul Perreault, who recently addressed the subject of patient-centric leadership at the 14th eyeforpharma Philadelphia Summit, says it’s about innately understanding the big picture, in other words the patient’s whole story, not just his or her medical condition.
“It requires understanding patients’ specific needs, what they’re going through, and the types of stresses these conditions place on them and their families,” Perreault says. “It also means providing not only treatment but resources and emotional support designed to improve outcomes and enhance quality of life and wellbeing.”
By Dennis Jackman
January 7, 2016
We often hear the question, ‘Why do drugs cost as much as they do?‘ In the U.S., the cost of drugs has become a campaign issue for some Presidential candidates, and Congressional task forces and committees have been exploring this question. Legislation has been introduced in some states to limit drug prices. And in Europe, there are steps toward joint negotiation of prices among some nations.
But what is often missing in statements about the cost of medicines and in proposed solutions is an answer to the fundamental question, ‘What is the value of pharmaceutical products to patients and the healthcare system versus the cost?‘ This is where the focus needs to be placed so that appropriate policy decisions can be made based on patient benefits, savings that drugs provide to the healthcare system, economic value, and the need to sustain valuable biopharmaceutical innovation, rather than a singular focus on drug costs.
Pennsylvania Bio’s CEO Roundtable brings biotech leaders together to discuss challenges facing the industry
September 17, 2015
By Christopher Florentz
CSL CEO and Managing Director Paul Perreault (center) responds to a question from the CEO Roundtable moderator.
Downturns in the global markets may have a significant adverse impact on some businesses, but CSL Behring isn’t one of them, CSL CEO and Managing Director Paul Perreault recently shared with more than 250 biotechnology leaders from the U.S. east coast.
“Organic growth is the base of our business,” Paul said at Pennsylvania Bio’s CEO Roundtable in King of Prussia, Pa. where CSL Behring is headquartered. Paul said CSL focuses its world-class research and development, high-quality manufacturing, and patient-centered management to develop and deliver innovative biotherapies and support programs – all to prevent and treat people with life-threatening medical conditions and help them live full lives.
“We’re a growing presence in China and in other emerging markets, in addition to those where we’re firmly established, such as Europe and North America. So we’re not impacted by downturns in the global economy to the extent that some businesses are.